JPH0573760B2 - - Google Patents

Info

Publication number: JPH0573760B2
Authority: JP; Japan
Prior art keywords: sample; tumor; dissolved; activity; vascular endothelial
Prior art date: 1984-02-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP59032199A

Other languages

English (en)

Japanese (ja)

Other versions

JPS60178820A (ja

Inventor

Fujio Suzuki

Yukio Kato

Juji Kai

Masaharu Takigawa

Takeshi Shiio

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Ajinomoto Co Inc

Original Assignee

Ajinomoto Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-02-22

Filing date

1984-02-22

Publication date

1993-10-15

1984-02-22 Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc

1984-02-22 Priority to JP59032199A priority Critical patent/JPS60178820A/ja

1985-09-12 Publication of JPS60178820A publication Critical patent/JPS60178820A/ja

1993-10-15 Publication of JPH0573760B2 publication Critical patent/JPH0573760B2/ja

Status Granted legal-status Critical Current

Links

230000000259 anti-tumor effect Effects 0.000 claims description 12
210000000845 cartilage Anatomy 0.000 claims description 10
239000002244 precipitate Substances 0.000 claims description 7
238000000108 ultra-filtration Methods 0.000 claims description 6
241001465754 Metazoa Species 0.000 claims description 4
239000000126 substance Substances 0.000 claims description 4
239000003125 aqueous solvent Substances 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 2
239000002904 solvent Substances 0.000 claims 1
239000000523 sample Substances 0.000 description 31
206010028980 Neoplasm Diseases 0.000 description 21
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 16
230000002401 inhibitory effect Effects 0.000 description 12
210000003556 vascular endothelial cell Anatomy 0.000 description 12
239000002504 physiological saline solution Substances 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
230000005764 inhibitory process Effects 0.000 description 9
230000004663 cell proliferation Effects 0.000 description 8
239000012153 distilled water Substances 0.000 description 8
230000006820 DNA synthesis Effects 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
210000004027 cell Anatomy 0.000 description 7
239000012528 membrane Substances 0.000 description 7
239000006228 supernatant Substances 0.000 description 7
241000283690 Bos taurus Species 0.000 description 6
230000001605 fetal effect Effects 0.000 description 6
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 6
230000000694 effects Effects 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 4
238000010828 elution Methods 0.000 description 4
229960000789 guanidine hydrochloride Drugs 0.000 description 4
238000002513 implantation Methods 0.000 description 4
238000000034 method Methods 0.000 description 4
239000000047 product Substances 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
210000004881 tumor cell Anatomy 0.000 description 4
229920000936 Agarose Polymers 0.000 description 3
230000010261 cell growth Effects 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
238000005259 measurement Methods 0.000 description 3
239000002609 medium Substances 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
239000012266 salt solution Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000013076 target substance Substances 0.000 description 3
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
208000001382 Experimental Melanoma Diseases 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
239000003855 balanced salt solution Substances 0.000 description 2
239000000287 crude extract Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
239000000203 mixture Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
210000002235 sarcomere Anatomy 0.000 description 2
239000000243 solution Substances 0.000 description 2
-1 As a control group Substances 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
229920002271 DEAE-Sepharose Polymers 0.000 description 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
102000013275 Somatomedins Human genes 0.000 description 1
239000013543 active substance Substances 0.000 description 1
238000005273 aeration Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
150000002357 guanidines Chemical class 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
210000001147 pulmonary artery Anatomy 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
239000012488 sample solution Substances 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

JP59032199A 1984-02-22 1984-02-22 抗腫瘍活性物質の製造方法 Granted JPS60178820A (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP59032199A JPS60178820A (ja)	1984-02-22	1984-02-22	抗腫瘍活性物質の製造方法

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP59032199A JPS60178820A (ja)	1984-02-22	1984-02-22	抗腫瘍活性物質の製造方法

Publications (2)

Publication Number	Publication Date
JPS60178820A JPS60178820A (ja)	1985-09-12
JPH0573760B2 true JPH0573760B2 (de)	1993-10-15

Family

ID=12352232

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP59032199A Granted JPS60178820A (ja)	1984-02-22	1984-02-22	抗腫瘍活性物質の製造方法

Country Status (1)

Country	Link
JP (1)	JPS60178820A (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5242692A (en) *	1990-07-10	1993-09-07	Bar Ilan University	Anti-metastatic factor
US6380366B1 (en)	1994-04-28	2002-04-30	Les Laboratoires Aeterna Inc.	Shark cartilage extract:process of making, methods of using and compositions thereof
CN1245993C (zh)	1997-03-11	2006-03-22	阿特纳赞塔里斯公司	用于治疗肿瘤的含有鲨鱼软骨提取物和抗肿瘤剂的药物组合物
US6168807B1 (en)	1998-07-23	2001-01-02	Les Laboratoires Aeterna Inc.	Low molecular weight components of shark cartilage, processes for their preparation and therapeutic uses thereof

1984
- 1984-02-22 JP JP59032199A patent/JPS60178820A/ja active Granted

Also Published As

Publication number	Publication date
JPS60178820A (ja)	1985-09-12

Similar Documents

Publication	Publication Date	Title
JP2594222B2 (ja)	1997-03-26	新規生理活性物質−ｋｆ
EP0069232A2 (de)	1983-01-12	Pharmazeutische Zusammensetzung enthaltend Phenylacetylglutamin, dessen Kombination mit Phenylessigsäure oder 3-(Phenylacetylamino)piperidin-2,6-dion,ein Verfahren zur Gewinnung dieser Stoffe aus Urin sowie ein Verfahren zur Herstellung von 3-(Phenylacetylamino)piperidin-2,6-dion
CA1199579A (en)	1986-01-21	Process for the purification of physiologically active substance having antitumor activity
EP0341209B1 (de)	1993-09-15	Physiologisch wirkende Substanzen, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen davon
JPH0573760B2 (de)	1993-10-15
JP3092874B2 (ja)	2000-09-25	乳清由来の骨芽細胞増殖・骨強化画分及び該画分を含有する骨強化食品、飼料、薬品類
NZ246211A (en)	1994-12-22	Osteoblast growth and bone enhancing factor(s) derived from whey and foods containing it
JPH0472840B2 (de)	1992-11-19
CN102268414B (zh)	2013-01-23	具有抗肿瘤细胞增殖活性的毛头鬼伞漆酶及其制备方法
JP3323765B2 (ja)	2002-09-09	細胞接着抑制剤
US4908206A (en)	1990-03-13	Extracts of embryonic organs, process for their preparation and pharmaceutical preparation containing them
JPS5939828A (ja)	1984-03-05	抗腫瘍活性物質の製造方法
US4676983A (en)	1987-06-30	Tumor cytostatic-citocidal factor from blood platelets
JP2714663B2 (ja)	1998-02-16	腸内有益菌増殖促進剤
JPH0341478B2 (de)	1991-06-24
KR100492940B1 (ko)	2005-06-02	항종양활성 증진용 조성물
JP2868800B2 (ja)	1999-03-10	癌転移抑制剤
JPH01313498A (ja)	1989-12-18	新規ペプチド
JPS6216428A (ja)	1987-01-24	ヒメヒオウギズイセンから得られる生物活性物質及びその製法
JP2002521341A (ja)	2002-07-16	抗癌および抗炎症効果を有する牛糞抽出物およびその製造方法
JPH02193984A (ja)	1990-07-31	水溶性２―アミノフェノキサジン―３―オンおよびその誘導体の製造方法
JPH02167299A (ja)	1990-06-27	棘皮動物由来の抗腫瘍性物質並びにその製造法
JPS58172321A (ja)	1983-10-11	桃の種子から得られる生物活性蛋白質ｐｒ−ａ及びｐｒ−ｂ並びにその製法
JPH0314521A (ja)	1991-01-23	抗腫瘍性物質の製造法
JPS6018680B2 (ja)	1985-05-11	新規なる糖蛋白質ｐｒｆ，その製造法および該糖蛋白質を有効成分として含有する制癌剤